FIGURE 5.

KDM7A promotes breast cell migration and invasion in vitro and in vivo. (A,B) MCF7 cells (A) and T47D cells (B) were transfected with indicated siRNAs followed by TGF-β treatment for 48 h. When the cells reached confluence, scratch wound was created by using a sterile micropipette tip. Photos were taken at 0 and 24 h after wound creation. The changes in side-to-side wound area were measured by Image-Pro. Data were expressed as % migration compared with control arbitrarily set as 100%. (C,D) MCF7 cells (C) and T47D cells (D) were transfected with indicated siRNAs. Cell invasion was examined by transwell assay. All experiments were performed in triplicate wells and repeated three times, and one representative experiment is shown. (E,F) Heterotopic xenograft assay was performed as described in the section “Materials and Methods.” N = 10 mice for each group. (G,H) In vivo metastasis was performed as described in the section “Materials and Methods.” N = 8 mice for each group. Data represent mean ± SD. *p < 0.05, two-tailed t-test. KDM7A depletion attenuated migration/invasion of breast cancer cells in vitro and partially blockaded metastasis of breast cancer cells in vivo. (I) Kaplan–Meier plot of survival in breast cancer patients with high and low KDM7A expression either singularly or in combination of RHOJ expression. Breast cancer patients with higher KDM7A/RHOJ expression displayed poorer survival.